AR095072A1 - Conjugados antibióticos - Google Patents

Conjugados antibióticos

Info

Publication number
AR095072A1
AR095072A1 ARP140100773A ARP140100773A AR095072A1 AR 095072 A1 AR095072 A1 AR 095072A1 AR P140100773 A ARP140100773 A AR P140100773A AR P140100773 A ARP140100773 A AR P140100773A AR 095072 A1 AR095072 A1 AR 095072A1
Authority
AR
Argentina
Prior art keywords
antibiotic conjugates
antibiotic
covalent bonds
conjugates
linker
Prior art date
Application number
ARP140100773A
Other languages
English (en)
Inventor
C Sinha Santosh
Chow Ken
E Garst Michael
Attar Mayssa
D Swift Brandon
Wang Liming
A Bhat Smita
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50382692&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR095072(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of AR095072A1 publication Critical patent/AR095072A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Botany (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Reivindicación 1: Una droga híbrida que comprende por lo menos dos porciones antibióticas, o una sal farmacéutica de la misma, que se conectan vía dos enlaces covalentes con un enlazador de manera que dichos enlaces covalentes se degradan in vivo para producir los antibióticos respectivos independientemente.
ARP140100773A 2013-03-08 2014-03-07 Conjugados antibióticos AR095072A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361775216P 2013-03-08 2013-03-08

Publications (1)

Publication Number Publication Date
AR095072A1 true AR095072A1 (es) 2015-09-16

Family

ID=50382692

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP140100773A AR095072A1 (es) 2013-03-08 2014-03-07 Conjugados antibióticos
ARP140100774A AR095073A1 (es) 2013-03-08 2014-03-07 Compuesto híbrido con una porción ciclosporina a y una porción de esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica y dicha composición

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP140100774A AR095073A1 (es) 2013-03-08 2014-03-07 Compuesto híbrido con una porción ciclosporina a y una porción de esteroide, uso de dicho compuesto para preparar una composición farmacéutica tópica y dicha composición

Country Status (16)

Country Link
US (4) US9402913B2 (es)
EP (2) EP2964268A1 (es)
JP (1) JP2016510754A (es)
KR (1) KR20150125663A (es)
CN (1) CN105025929A (es)
AR (2) AR095072A1 (es)
AU (1) AU2014225637A1 (es)
BR (1) BR112015021388A2 (es)
CA (1) CA2899500A1 (es)
CL (1) CL2015002210A1 (es)
IL (1) IL240920A0 (es)
PH (1) PH12015501857A1 (es)
RU (1) RU2015135145A (es)
SG (1) SG11201507241UA (es)
TW (2) TW201511758A (es)
WO (4) WO2014138437A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507241UA (en) 2013-03-08 2015-10-29 Allergan Inc Cyclosporine a-steroid conjugates
CN105073140A (zh) 2013-03-08 2015-11-18 阿勒根公司 与类固醇药物直接键联的抗生素缀合物
JP7366406B2 (ja) 2017-01-03 2023-10-23 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル 生分解性の抗菌性足場としての一酸化窒素放出性アルギン酸塩およびそれに関する方法
WO2018178902A1 (en) 2017-03-28 2018-10-04 The University Of North Carolina At Chapel Hill Nitric oxide-releasing polyaminoglycosides as biodegradable antibacterial scaffolds and methods pertaining thereto
WO2019148291A1 (en) 2018-02-02 2019-08-08 Interface Biologics, Inc. Ocular inserts comprising a covalently linked steroid dimer
CA3091458A1 (en) 2018-03-06 2019-09-12 The University Of North Carolina At Chapel Hill Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2020041378A1 (en) * 2018-08-22 2020-02-27 Bacainn Therapeutics, Inc. Cyclosporine compositions and methods of use
AU2019328590B2 (en) * 2018-08-31 2023-04-13 Aerie Pharmaceuticals, Inc. Isoquinoline-steroid conjugates and uses thereof
US11421044B2 (en) 2018-12-28 2022-08-23 The University Of North Carolina At Chapel Hill Nitric oxide-releasing antibacterial polymers and scaffolds fabricated therefrom and methods pertaining thereto
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders
WO2023079362A1 (en) * 2021-11-03 2023-05-11 Ripple Therapeutics Corporation Processable compositions and use for the same

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2999102A (en) 1959-10-14 1961-09-05 Thomae Gmbh Dr K Bis-(steroid-21)-dicarboxylic acid esters
US3147183A (en) 1962-04-16 1964-09-01 Boehringer Sohn Ingelheim Bis-(steroid-21)-dicarboxylic acid esters
US3916002A (en) * 1973-12-17 1975-10-28 Taubert Hans Dieter Oligomeric steroid esters, process for their production, and therapeutic compositions containing the same
EP0194972B1 (en) 1985-03-11 1992-07-29 Sandoz Ag Novel cyclosporins
JPH089597B2 (ja) 1986-01-21 1996-01-31 杏林製薬株式会社 選択毒性に優れた８‐アルコキシキノロンカルボン酸およびその塩並びにその製造方法
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
EP0629292A1 (en) 1993-01-06 1994-12-21 Beckman Instruments, Inc. Method for making a preconjugate
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
CA2136803A1 (en) 1993-12-22 1995-06-23 Kazumi Ogata Steroid derivatives
US6051576A (en) 1994-01-28 2000-04-18 University Of Kentucky Research Foundation Means to achieve sustained release of synergistic drugs by conjugation
AU705226B2 (en) 1994-01-28 1999-05-20 University Of Kentucky Research Foundation, The Codrugs as a method of controlled drug delivery
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
US6350422B1 (en) 1998-09-21 2002-02-26 Phillips Petroleum Company Sorbent compositions
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
AU4934299A (en) 1999-07-15 2001-02-05 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US20010049366A1 (en) * 2000-02-09 2001-12-06 Alcon Universal Ltd. Topical solution formulations containing an antibiotic and a corticosteroid
US6306842B1 (en) 2000-06-02 2001-10-23 Medinox, Inc. Protected forms of a combination of pharmacologically active agents and uses therefor
KR20040005936A (ko) * 2001-04-26 2004-01-16 컨트롤 딜리버리 시스템즈 인코포레이티드 공동약물을 함유하는 서방 약물 전달 시스템
WO2003031441A1 (en) 2001-10-04 2003-04-17 Morphochen Aktiengesellschaft Für Kombinatorische Chemie Multiple action compounds
WO2003031443A1 (en) 2001-10-04 2003-04-17 Morphochem Aktiengesellschaft für kombinatorische Chemie Dual actions antibiotics comprising a oxazoldinone and a quinolone or naphthyridinone moiety
AUPR879601A0 (en) * 2001-11-09 2001-12-06 Biota Scientific Management Pty Ltd Novel chemical compounds and their use
JP2005518354A (ja) 2001-11-19 2005-06-23 コントロール・デリバリー・システムズ・インコーポレイテッド コドラッグを含有する医薬組成物
AU2004222306A1 (en) 2003-03-17 2004-09-30 Albany Molecular Research, Inc. Novel cyclosporins
HRP20030324A2 (en) 2003-04-24 2005-02-28 Pliva-Istra�iva�ki institut d.o.o. Compounds of antiinflammatory effect
CA2529347C (en) 2003-04-30 2011-09-06 Morphochem Aktiengesellschaft Fur Kombinatorische Chemie Use of oxazolidinone-quinoline hybrid antibiotics for the treatment of anthrax and other infections
WO2004112838A2 (en) 2003-05-21 2004-12-29 Control Delivery Systems, Inc. Codrugs of diclofenac
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
US7288520B2 (en) 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
WO2008069824A2 (en) 2006-02-27 2008-06-12 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for transport of molecules with enhanced release properties across biological barriers
WO2008094507A2 (en) 2007-01-26 2008-08-07 Cellicon Biotechnologies, Inc. Novel fusion compounds
ITMI20080382A1 (it) * 2008-03-07 2009-09-08 Ctg Pharma S R L Composizioni farmaceutiche oculari
CA2730108A1 (en) 2008-07-10 2010-01-14 Allergan, Inc. Cyclosporin derivatives for treating ocular and dermal diseases and conditions
MX2008014515A (es) * 2008-09-09 2010-04-29 Allergan Inc Suspension oftalmica para uso ocular.
EP2413974B1 (en) * 2009-03-31 2016-03-23 Technion Research & Development Foundation Ltd. Conjugated antimicrobial agents
JP2012528163A (ja) 2009-05-27 2012-11-12 アラーガン、インコーポレイテッド 炎症性疾患および状態を処置するためのシクロスポリン誘導体
US9175042B2 (en) 2010-10-12 2015-11-03 Allergan, Inc. Cyclosporin analogs
SG189880A1 (en) 2010-10-12 2013-06-28 Allergan Inc Cyclosporin analogs
SG11201400652UA (en) 2011-09-16 2014-09-26 Davidson Lopez Llc Plant steroids and uses thereof
WO2013181339A2 (en) 2012-06-01 2013-12-05 Allergan, Inc. Cyclosporin a analogs
US20140256666A1 (en) 2013-03-08 2014-09-11 Allergan, Inc. Antibiotic conjugates with nonsteroidal anti-inflammatory drugs
SG11201507241UA (en) 2013-03-08 2015-10-29 Allergan Inc Cyclosporine a-steroid conjugates
CN105073140A (zh) 2013-03-08 2015-11-18 阿勒根公司 与类固醇药物直接键联的抗生素缀合物
KR20150128856A (ko) 2013-03-08 2015-11-18 알러간, 인코포레이티드 스테로이드 약물과 결합된 항생제 컨쥬게이트

Also Published As

Publication number Publication date
CN105025929A (zh) 2015-11-04
RU2015135145A (ru) 2017-04-13
US9402913B2 (en) 2016-08-02
BR112015021388A2 (pt) 2017-07-18
CA2899500A1 (en) 2014-09-12
KR20150125663A (ko) 2015-11-09
US20140256694A1 (en) 2014-09-11
SG11201507241UA (en) 2015-10-29
EP2964269A1 (en) 2016-01-13
CL2015002210A1 (es) 2016-01-22
TW201511758A (zh) 2015-04-01
WO2014138437A1 (en) 2014-09-12
TW201511768A (zh) 2015-04-01
WO2014138403A1 (en) 2014-09-12
IL240920A0 (en) 2015-10-29
WO2014138425A1 (en) 2014-09-12
WO2014138359A1 (en) 2014-09-12
AR095073A1 (es) 2015-09-16
US20140256696A1 (en) 2014-09-11
JP2016510754A (ja) 2016-04-11
PH12015501857A1 (en) 2015-12-07
AU2014225637A1 (en) 2015-09-03
US20140256658A1 (en) 2014-09-11
EP2964268A1 (en) 2016-01-13
US20140256651A1 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
AR095072A1 (es) Conjugados antibióticos
UY36075A (es) Derivados de tubulisina
BR112015027322A8 (pt) Compostos antissenso conjugados e sua utilização
PH12016501411A1 (en) Bifunctional cytotoxic agents
PE20150892A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
UY36186A (es) Ácidos grasos novedosos y su uso en la conjugación con biomoléculas
DK3283521T3 (da) Lægemiddelkonjugater, der omfatter antistoffer mod claudin 18.2
MX2021010550A (es) Conjugados de anticuerpo-farmaco hidrofilicos.
EA201690780A1 (ru) Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
EP3307749A4 (en) HYDROPHILIC LINKER FOR CONJUGATION
EP3082797A4 (en) Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
EA201992456A2 (ru) Самостабилизирующиеся линкерные конъюгаты
CL2012000092A1 (es) Compuestos derivados de piridina y pirazina o una sal de los mismos, moduladores de proteina quinasa cdk9; composicion farmaceutica que los comprende, util para el tratamiento del cancer, hipotrofia cardiaca, vih y enfermedades inflamatorias.
NZ703581A (en) Anti-cd70 antibody drug conjugates
BR112015021134A2 (pt) conjugados de fármaco e anticorpo
WO2015067570A3 (en) Pharmaceutical combinations comprising cd33 antibodies and de-methylating agents
BR112015011118A2 (pt) conjugado; composição farmacêutica; e uso de um ou mais dos conjugados
MX2017008215A (es) Conjugados de farmacos proteinas de union que comprenden derivados de antraciclina.
ECSP13013060A (es) Composiciones de nucleasa terapéuticas y métodos
EP3086815A4 (en) Sulfonamide-containing linkage systems for drug conjugates
CL2016000009A1 (es) Tratamiento de rosacea papulopustular con ivermectina.
EP2968600A4 (en) Antibody drug conjugates
EP3077006A4 (en) Polymer-carbohydrate conjugates for drug delivery technology
CY1121852T1 (el) Μορφοποιησεις και μεθοδοι παρασκευης μορφοποιησεων για χρηση στον καθαρισμο του παχεος εντερου
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.

Legal Events

Date Code Title Description
FB Suspension of granting procedure